Obesity, inflammation, and atherosclerosis

[1]  J. Geddes,et al.  What is a randomised controlled trial? , 2009, Epidemiologia e Psichiatria Sociale.

[2]  Merlin C. Thomas,et al.  Direct antiatherosclerotic effects of PPAR agonists , 2009, Current opinion in lipidology.

[3]  M. Bennett,et al.  Cause or consequence: what does macrophage apoptosis do in atherosclerosis? , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[4]  D. Mozaffarian,et al.  Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2009, Circulation.

[5]  M. Bennett,et al.  What Does Macrophage Apoptosis Do in Atherosclerosis? , 2009 .

[6]  G. Hansson.  Atherosclerosis--an immune disease: The Anitschkov Lecture 2007. , 2009, Atherosclerosis.

[7]  J. Bunt,et al.  The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomised double-blind placebo-controlled study , 2009, Diabetologia.

[8]  P. Libby,et al.  Toll-Like Receptor 2 Mediates Apolipoprotein CIII–Induced Monocyte Activation: Retracted , 2008, Circulation research.

[9]  T. Kita,et al.  Inhibition of CCR2 Ameliorates Insulin Resistance and Hepatic Steatosis in db/db Mice , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[10]  P. Libby,et al.  Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. , 2008, The New England journal of medicine.

[11]  N. Paynter,et al.  C-Reactive Protein and Parental History Improve Global Cardiovascular Risk Prediction: The Reynolds Risk Score for Men , 2008, Circulation.

[12]  J. Olefsky,et al.  Insulin sensitivity: modulation by nutrients and inflammation. , 2008, The Journal of clinical investigation.

[13]  P. Libby,et al.  Interferon- (cid:1) , a Th1 Cytokine, Regulates Fat Inflammation A Role for Adaptive Immunity in Obesity , 2022 .

[14]  V. Hombach,et al.  T-lymphocyte Infiltration in Visceral Adipose Tissue: A Primary Event in Adipose Tissue Inflammation and the Development of Obesity-Mediated Insulin Resistance , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[15]  Chih-Hao Lee,et al.  Adipocyte-derived Th2 cytokines and myeloid PPARdelta regulate macrophage polarization and insulin sensitivity. , 2008, Cell metabolism.

[16]  F. Mach,et al.  A Novel RANTES Antagonist Prevents Progression of Established Atherosclerotic Lesions in Mice , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[17]  P. Libby,et al.  The multiple facets of the fat tissue. , 2008, Thyroid : official journal of the American Thyroid Association.

[18]  T. McDonald,et al.  Monocyte Chemoattractant Protein-1 Deficiency Fails to Restrain Macrophage Infiltration Into Adipose Tissue , 2008, Diabetes.

[19]  Johan Kuiper,et al.  CXCR3 Antagonist NBI-74330 Attenuates Atherosclerotic Plaque Formation in LDL Receptor–Deficient Mice , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[20]  B. Gersh.  Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes , 2008 .

[21]  K. Furie,et al.  Heart disease and stroke statistics--2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2008, Circulation.

[22]  Graham M Lord,et al.  Absence of CC Chemokine Ligand 2 Does Not Limit Obesity-Associated Infiltration of Macrophages Into Adipose Tissue , 2007, Diabetes.

[23]  Hideki Katagiri,et al.  Adiposity and Cardiovascular Disorders: Disturbance of the Regulatory System Consisting of Humoral and Neuronal Signals , 2007, Circulation research.

[24]  Frank Brombacher,et al.  Macrophage-specific PPARγ controls alternative activation and improves insulin resistance , 2007, Nature.

[25]  P. Ridker.  C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. , 2007, Journal of the American College of Cardiology.

[26]  Leif E. Peterson,et al.  T-Cell Accumulation and Regulated on Activation, Normal T Cell Expressed and Secreted Upregulation in Adipose Tissue in Obesity , 2007, Circulation.

[27]  N. Cook,et al.  Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. , 2007, JAMA.

[28]  J. Plutzky,et al.  Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. , 2007, Circulation.

[29]  F. Tacke,et al.  Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. , 2007, The Journal of clinical investigation.

[30]  S. Gordon.  Macrophage heterogeneity and tissue lipids. , 2007, The Journal of clinical investigation.

[31]  A. Saltiel,et al.  Obesity induces a phenotypic switch in adipose tissue macrophage polarization. , 2007, The Journal of clinical investigation.

[32]  P. Libby,et al.  Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. , 2007, The Journal of clinical investigation.

[33]  Christian Weber,et al.  Ccr5 But Not Ccr1 Deficiency Reduces Development of Diet-Induced Atherosclerosis in Mice , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[34]  G. Hotamisligil,et al.  Inflammation and metabolic disorders , 2006, Nature.

[35]  C. Block,et al.  Mechanisms linking obesity with cardiovascular disease , 2006, Nature.

[36]  P. Ridker,et al.  The relative strength of C-reactive protein and lipid levels as determinants of ischemic stroke compared with coronary heart disease in women. , 2006, Journal of the American College of Cardiology.

[37]  J. Flier,et al.  TLR4 links innate immunity and fatty acid-induced insulin resistance. , 2006, The Journal of clinical investigation.

[38]  T. Littlewood,et al.  Apoptosis of vascular smooth muscle cells induces features of plaque vulnerability in atherosclerosis , 2006, Nature Medicine.

[39]  D. Steinberg,et al.  Thematic review series : The Pathogenesis of Atherosclerosis An interpretive history of the cholesterol controversy , part V : The discovery of the statins and the end of the controversy 1 , 2006 .

[40]  Peter Libby,et al.  The immune response in atherosclerosis: a double-edged sword , 2006, Nature Reviews Immunology.

[41]  R. Kitazawa,et al.  MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. , 2006, The Journal of clinical investigation.

[42]  K. Moore,et al.  Chemokine CXCL10 Promotes Atherogenesis by Modulating the Local Balance of Effector and Regulatory T Cells , 2006, Circulation.

[43]  Shinji Kihara,et al.  Adiponectin: a key adipocytokine in metabolic syndrome. , 2006, Clinical science.

[44]  R. Flavell,et al.  Natural regulatory T cells control the development of atherosclerosis in mice , 2006, Nature Medicine.

[45]  R. Leibel,et al.  CCR2 modulates inflammatory and metabolic effects of high-fat feeding. , 2006, The Journal of clinical investigation.

[46]  D. Steinberg.  Thematic review series: The Pathogenesis of Atherosclerosis. An interpretive history of the cholesterol controversy, part IV: The 1984 Coronary Primary Prevention Trial ends it—almost1 , 2006, Journal of Lipid Research.

[47]  G. Hansson,et al.  Chemokines as potential therapeutic targets in atherosclerosis. , 2006, Current drug targets.

[48]  Shupei Wang,et al.  Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans Published, JLR Papers in Press, September 8, 2005. DOI 10.1194/jlr.M500294-JLR200 , 2005, Journal of Lipid Research.

[49]  Erland Erdmann,et al.  Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial , 2005, The Lancet.

[50]  A. Hoffmann,et al.  Molecular Determinants of Crosstalk between Nuclear Receptors and Toll-like Receptors , 2005, Cell.

[51]  L. Niskanen,et al.  C-reactive protein in the prediction of cardiovascular and overall mortality in middle-aged men: a population-based cohort study. , 2005, European heart journal.

[52]  J. Polak,et al.  C-Reactive Protein and the 10-Year Incidence of Coronary Heart Disease in Older Men and Women: The Cardiovascular Health Study , 2005, Circulation.

[53]  Nikolaus Marx,et al.  Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. , 2005, Journal of the American College of Cardiology.

[54]  P. Scherer,et al.  Adipose tissue, inflammation, and cardiovascular disease. , 2005, Circulation research.

[55]  R. Kronmal,et al.  Azithromycin for the secondary prevention of coronary events. , 2005, The New England journal of medicine.

[56]  S. Olshansky,et al.  A potential decline in life expectancy in the United States in the 21st century. , 2005, The New England journal of medicine.

[57]  B. Richelsen,et al.  Adiponectin: action, regulation and association to insulin sensitivity , 2005, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[58]  D. Steinberg.  Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy: part II: the early evidence linking hypercholesterolemia to coronary disease in humans. , 2005, Journal of lipid research.

[59]  M. Pfeffer,et al.  C-reactive protein levels and outcomes after statin therapy. , 2005, The New England journal of medicine.

[60]  A. Hevener,et al.  IKK-beta links inflammation to obesity-induced insulin resistance. , 2005, Nature medicine.

[61]  D. Steinberg.  The Pathogenesis of Atherosclerosis An interpretive history of the cholesterol controversy , part III : mechanistically defining the role of hyperlipidemia 1 , 2005 .

[62]  Jing Ma,et al.  Inflammatory markers and the risk of coronary heart disease in men and women. , 2004, The New England journal of medicine.

[63]  Roger A. Davis,et al.  Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARα, β/δ, and γ , 2004 .

[64]  D. Steinberg.  Thematic review series: The Pathogenesis of Atherosclerosis. An interpretive history of the cholesterol controversy: part I Published, JLR Papers in Press, April 21, 2004. DOI 10.1194/jlr.R400003-JLR200 11 Based in part on The Cholesterol Wars, a book in preparation. , 2004, Journal of Lipid Research.

[65]  Vilmundur Gudnason,et al.  C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. , 2004, The New England journal of medicine.

[66]  John A Wagner,et al.  Complex Distribution, Not Absolute Amount of Adiponectin, Correlates with Thiazolidinedione-mediated Improvement in Insulin Sensitivity* , 2004, Journal of Biological Chemistry.

[67]  C. Meisinger,et al.  C-Reactive Protein Modulates Risk Prediction Based on the Framingham Score: Implications for Future Risk Assessment: Results From a Large Cohort Study in Southern Germany , 2004, Circulation.

[68]  Heejung Bang,et al.  Lipoprotein-Associated Phospholipase A2, High-Sensitivity C-Reactive Protein, and Risk for Incident Coronary Heart Disease in Middle-Aged Men and Women in the Atherosclerosis Risk in Communities (ARIC) Study , 2004, Circulation.

[69]  F. Mach,et al.  Antagonism of RANTES Receptors Reduces Atherosclerotic Plaque Formation in Mice , 2004, Circulation research.

[70]  Roger A. Davis,et al.  Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma. , 2004, The Journal of clinical investigation.

[71]  M. Desai,et al.  Obesity is associated with macrophage accumulation in adipose tissue. , 2003, The Journal of clinical investigation.

[72]  L. Tartaglia,et al.  Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. , 2003, The Journal of clinical investigation.

[73]  J. Kaski,et al.  The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. , 2003, Journal of the American College of Cardiology.

[74]  Christopher M O'Connor,et al.  Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. , 2003, JAMA.

[75]  P. Tipping,et al.  The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. , 2003, The American journal of pathology.

[76]  C. Come,et al.  Influence of Interferon-&ggr; on the Extent and Phenotype of Diet-Induced Atherosclerosis in the LDLR-Deficient Mouse , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[77]  P. Debré,et al.  Decreased Atherosclerotic Lesion Formation in CX3CR1/Apolipoprotein E Double Knockout Mice , 2003, Circulation.

[78]  I. Charo,et al.  Decreased atherosclerosis in CX3CR1-/- mice reveals a role for fractalkine in atherogenesis. , 2003, The Journal of clinical investigation.

[79]  Gary L Myers,et al.  Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. , 2003, Circulation.

[80]  J. Michel,et al.  Interleukin-10 Deficiency Increases Atherosclerosis, Thrombosis, and Low-density Lipoproteins in Apolipoprotein E Knockout Mice , 2003, Molecular medicine.

[81]  S. Gordon.  Alternative activation of macrophages , 2003, Nature Reviews Immunology.

[82]  P. Libby.  Inflammation in atherosclerosis , 2002, Nature.

[83]  Michael Karin,et al.  A central role for JNK in obesity and insulin resistance , 2002, Nature.

[84]  P. Libby,et al.  Progression of Atheroma: A Struggle Between Death and Procreation , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[85]  Akira Takeshita,et al.  Anti-Monocyte Chemoattractant Protein-1 Gene Therapy Limits Progression and Destabilization of Established Atherosclerosis in Apolipoprotein E–Knockout Mice , 2002, Circulation.

[86]  A. Daugherty,et al.  Interleukin-4 Deficiency Decreases Atherosclerotic Lesion Formation in a Site-Specific Manner in Female LDL Receptor−/− Mice , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[87]  C. Janeway,et al.  Innate immune recognition. , 2002, Annual review of immunology.

[88]  Ose,et al.  Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events* , 2002 .

[89]  A. Tedgui,et al.  Inhibition of Transforming Growth Factor- Signaling Accelerates Atherosclerosis and Induces an Unstable Plaque Phenotype in Mice , 2001 .

[90]  Michael Karin,et al.  Reversal of Obesity- and Diet-Induced Insulin Resistance with Salicylates or Targeted Disruption of Ikkβ , 2001, Science.

[91]  J. Manson,et al.  C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. , 2001, JAMA.

[92]  Paul M. Ridker,et al.  Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. , 2001, The New England journal of medicine.

[93]  N Rifai,et al.  Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. , 2001, JAMA.

[94]  C. Kataoka,et al.  New Anti-Monocyte Chemoattractant Protein-1 Gene Therapy Attenuates Atherosclerosis in Apolipoprotein E-Knockout Mice , 2001, Circulation.

[95]  Andrew C. Li,et al.  Peroxisome proliferator–activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor–deficient mice , 2000 .

[96]  T. Willson,et al.  Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. , 2000, The Journal of clinical investigation.

[97]  M. Visser,et al.  Elevated C-reactive protein levels in overweight and obese adults. , 1999, JAMA.

[98]  P. Libby,et al.  Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells. , 1999, The Journal of clinical investigation.

[99]  U. Andersson,et al.  Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. , 1999, Atherosclerosis.

[100]  K. Williams,et al.  Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.

[101]  S. Coppack,et al.  C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[102]  P Bailey,et al.  Double Edged Sword , 2002 .

[103]  M. Pfeffer,et al.  Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. , 1998, Circulation.

[104]  I. Charo,et al.  Decreased lesion formation in CCR2−/− mice reveals a role for chemokines in the initiation of atherosclerosis , 1998, Nature.

[105]  P. Libby,et al.  Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. , 1998, Molecular cell.

[106]  P. Libby,et al.  Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-alpha and matrix metalloproteinase expression. , 1998, Circulation.

[107]  P. Libby,et al.  Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. , 1997, Circulation.

[108]  A. Tall,et al.  IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. , 1997, The Journal of clinical investigation.

[109]  P. Ridker,et al.  Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. , 1997, The New England journal of medicine.

[110]  J. Witztum,et al.  T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[111]  B. Spiegelman,et al.  Tumor necrosis factor alpha inhibits signaling from the insulin receptor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[112]  P. Libby,et al.  An atherogenic diet rapidly induces VCAM-1, a cytokine-regulatable mononuclear leukocyte adhesion molecule, in rabbit aortic endothelium. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

[113]  B. Spiegelman,et al.  Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. , 1993, Science.

[114]  P. Libby,et al.  Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[115]  R. Kronmal,et al.  The Cardiovascular Health Study: design and rationale. , 1991, Annals of epidemiology.

[116]  D. Steinberg,et al.  Role of oxidised low density lipoprotein in atherogenesis. , 1993, British heart journal.

[117]  D. O'sullivan,et al.  1,2-Diacylglycerol and ceramide levels in insulin-resistant tissues of the rat in vivo. , 1990, The Journal of biological chemistry.

[118]  G. Gabbiani,et al.  Interferon gamma inhibits both proliferation and expression of differentiation-specific alpha-smooth muscle actin in arterial smooth muscle cells , 1989, The Journal of experimental medicine.

[119]  R. Friesel,et al.  Inhibition of endothelial cell proliferation by gamma-interferon , 1987, The Journal of cell biology.

[120]  S. Moore,et al.  Pathogenesis of atherosclerosis. , 1985, Metabolism: clinical and experimental.

[121]  R. Ross,et al.  Hyperlipidemia and atherosclerosis. , 1976, Science.

[122]  R. Ross,et al.  The pathogenesis of atherosclerosis (first of two parts). , 1976, The New England journal of medicine.